GlassScriptPhysician profile
Huachen Wei
NPI 1235167313
$252,133.24
in general payments reported to CMS, 2019-2025
38 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $15K · 2021: $8,895 · 2022: $35K · 2023: $43K · 2024: $34K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Food and Beverage: $14K · Travel and Lodging: $4,501 · Consulting Fee: $1,650 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,590.50 |
| Food and Beverage | $13,856.76 |
| Travel and Lodging | $4,501.19 |
| Consulting Fee | $1,650.00 |
| Education | $270.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75,044.63 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $62,490.97 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $53,315.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $17,321.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $13,854.87 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $13,617.22 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Celgene Corporation | $6,888.90 | 2019 | |
| Pfizer INC. | $1,166.17 | 2019-2025 | |
| Genzyme Corporation | $1,125.47 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $774.80 | 2019-2025 | Ilumya |
| Dermavant Sciences, INC. | $771.01 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $744.19 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $603.71 | 2020-2025 | Adbry, Anzupgo |
| Amgen INC. | $573.00 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $518.13 | 2019-2025 | Dupixent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $512.70 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $363.33 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $305.99 | 2024-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $268.84 | 2021-2025 | Valchlor |
| Merz North America, INC. | $264.57 | 2019-2022 | |
| Organon LLC | $203.76 | 2025 | Vtama, Nexplanon |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $201.87 | 2019-2023 | Targretin, Siliq |
| Gilead Sciences, INC. | $194.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $185.28 | 2019-2022 | |
| Dermira, INC. | $174.29 | 2019-2021 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.79 | 2022-2023 | Cyltezo |
| Prugen, INC. Pharmaceuticals | $82.25 | 2019-2020 | |
| Cipher Pharmaceuticals US LLC | $37.64 | 2025 | Spinosad, Natroba |
| Phadia US INC. | $37.34 | 2022-2023 | Immunocap |
| Strata Skin Sciences, INC. | $27.23 | 2022-2023 | Xtrac |
| Smith+Nephew, INC. | $22.05 | 2025 | Collagenase Santyl |
| Sanofi US Services INC. | $21.00 | 2025 | |
| Allergan, INC. | $18.07 | 2020 | |
| Lnhc, INC | $17.89 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $13.20 | 2023 | |
| Mayne Pharma Commercial LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huachen Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.